面向臨床藥物開發的 AI 成功率分析平台

Unlearn.AI builds AI-generated digital twins of clinical trial participants — forecasts of how each individual patient's outcomes would evolve — and uses them to sharpen design, interim, and readout decisions in drug development.
網站月造訪量估算
資料為該網域的 Similarweb 流量估算,不是活躍使用者數。僅顯示有資料的統計月份;擷取時間與流量統計月份分別標示。
擷取於 2026年11月11日

這是編輯給出的評估,滿分 5 分,不是使用者評分的平均值。 本頁的各方觀點由 AI 根據產品資訊歸納,不是真實使用者的評價。
依據 OpenAITools.app 於 2026-11-11 查驗的觀測資料,Unlearn.AI(unlearn.ai)是收錄於 AI 醫療健康的 AI 平台,每月產生 1.71萬次造訪,月流量變化量為 -8233(-32.5%)。其主要地理市場為美國(流量佔比 69.4%),並採用需聯絡報價定價模式。依每月流量計算的主要競爭替代方案包括 Intelligencia AI(每月 3872 次造訪),Cradle(每月 1.7萬次造訪),Floatz(每月 253 次造訪)。
數位分身幫臨床試驗省下超多對照組病人,這技術太猛了。
合規性做得很好,大型藥廠必備神器。
以下短評基於實時網頁探查、定價機制與同類基準由 AI 綜合生成,用於呈現不同情境下的常見亮點與槽點,非實名真實用戶留言。
Model-based forecasts of each participant's clinical outcomes, generated from baseline data already collected, that act as a virtual comparator or as additional information per enrolled patient.
A twin-based covariate adjustment approach that Unlearn describes as EMA-qualified and FDA-supported, used to reduce sample size in randomized controlled trials while maintaining power.
Build and compare design scenarios — endpoints, eligibility criteria, sample size, assumptions — so governance decisions are made with quantified tradeoffs instead of positions.
Pre-specified twin-based analyses added to the statistical analysis plan before unblinding, plus twin-adjusted analysis delivered at interim and at readout.
Design single-arm and externally controlled studies where randomization is not an option, selecting eligibility criteria that give open-label studies the best chance of a clear readout.
Unlearn.AI builds AI-generated digital twins of clinical trial participants — forecasts of how each individual patient's outcomes would evolve — and uses them to sharpen design, interim, and readout decisions in drug development.
Simulate expected enrollees against real eligibility criteria, then evaluate sample size and endpoints to lock in a smaller, lower-cost design before governance review.
Raise power at interim looks and in subgroup analyses without adding participants by incorporating twin-based covariate adjustment into the statistical analysis plan.
Re-analyze finished studies with digital twins to contextualize variability, improve endpoint sensitivity, and inform whether and how the program continues.
Use digital twins as the comparator in open-label or single-arm studies where randomization is impractical, tightening the evidence for regulators.
同一分類下同類 AI 工具的流量並排比較
| 排名 | AI 工具 | 每月造訪次數 | 月增幅 | 直接流量占比 | 價格 | 正面對決 |
|---|---|---|---|---|---|---|
| ● | Unlearn.AI | 1.71萬 | -32.5% | 44% 直接流量 | 需聯絡報價 | 目前產品 |
| 1 | Intelligencia AI | 3872 | -31.9% | 27% 直接流量 | 需聯絡報價 | 對比 Intelligencia AI |
| 2 | Cradle | 1.7萬 | -22.3% | 37% 直接流量 | 需聯絡報價 | 對比 Cradle |
| 3 | Floatz | 253 | -36.8% | 37% 直接流量 | 需聯絡報價 | 對比 Floatz |
| 4 | Delve AI | 4.9萬 | -4.6% | 40% 直接流量 | 免費增值 | 對比 Delve AI |
| 5 | Dr.Oracle | 72.38萬 | -1.2% | 12% 直接流量 | 免費試用 | 對比 Dr.Oracle |
| 6 | Aitia(gnshealthcare.com) | 0 | 0% | — | 需聯絡報價 | 對比 Aitia(gnshealthcare.com) |
面向臨床藥物開發的 AI 成功率分析平台
Sinkove generates synthetic biomedical images and anatomy data using AI, giving researchers and healthcare teams privacy-safe visual datasets to accelerate clinical research, model training and virtual trials.
用 AI 找出符合篩檢條件的病患,並為每顆肺結節評風險分
免費 / 開源以數位孿生社會模擬優化廣告與受眾洞察
免費 / 開源面向營養與代謝數據的健康智慧基礎設施